Ultragenyx Pharma (RARE) Tops Q3 EPS by 14c, Revenues Beat

Ultragenyx Pharma (RARE) Prices 4.44M Share Common Offering at $90/Sh

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced the pricing of its underwritten public offering of 4,444,444 shares of its common stock at a price to... More

Ultragenyx Pharma (RARE) PT Raised to $116 at Cowen

Cowen analyst Yaron Werber raised the price target on Ultragenyx Pharma (NASDAQ: RARE) to $116.00 (from $90.00) while maintaining an Outperform rating.

The analyst commented, "RARE reported Q3:20 earnings with OpEx of $132M v our $128M estimates & steady growth in sales of Crysvita & Dojolvi.... More

GeneTx and Ultragenyx (RARE) Announce Positive Interim Phase 1/2 Data on Investigational GTX-102 Demonstrating Improvement in Patients with Angelman Syndrome

GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), companies partnered in the development of intrathecally administered GTX-102, an investigational treatment for Angelman syndrome, today announced positive interim data from the Phase 1/2 study of GTX-102. Preliminary results from the first five patients treated indicate substantial improvements in all patients in at least two disease domains including communication, behavior, sleep, gross motor function, and fine motor function as measured by the Clinical Global Impression of Improvement Scale for Angelman Syndrome (CGI-I-AS) at day 128. At the highest doses, all five patients experienced a serious adverse event... More

Pre-Open Stock Movers 10/23: (SAVA) (SLDB) (SAM) Higher; (LLNW) (USX) (INTC) Lower (more...)

Today's Pre-Open Stock Movers:

Limelight Networks (NASDAQ: LLNW) 21.5% LOWER; reported Q3 EPS of ($0.01), $0.03 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $59.2 million versus the consensus estimate of $58.94 million. Limelight Networks sees FY2020 EPS of ($0.02)-$0.08, versus the consensus of $0.08. Limelight Networks sees FY2020 revenue of $230-240 million, versus the consensus of $236.59 million.

yberoptics Corp (NASDAQ:... More

Solid Biosciences (SLDB) Climbs 26% Following Pact with Ultragenyx Pharma (RARE) in DMD

Solid Biosciences (NASDAQ: SLDB) Climbs 26% Following Pact with Ultragenyx Pharma (NASDAQ: RARE) in DMD

Ultragenyx (RARE), Solid Biosciences (SLDB) Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for DMD

Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare diseases, and Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced a strategic collaboration and license agreement to focus on the development and commercialization of new gene therapies for Duchenne. The parties will collaborate to develop products that combine Solids differentiated microdystrophin construct, Ultragenyxs HeLa producer cell line (PCL) manufacturing platform, and AAV8... More